Cencora (NYSE:COR) Releases FY25 Earnings Guidance

Cencora (NYSE:COR) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share guidance of $14.80-15.10 for the period, compared to the consensus earnings per share estimate of $14.76. The company issued revenue guidance of +7-9% yr/yr to ~$314.6-320.5 billion, compared to the consensus revenue estimate of $312.40 billion. Cencora also updated its FY 2025 guidance to 14.800-15.100 EPS.

Cencora Price Performance

Shares of NYSE:COR opened at $240.51 on Wednesday. The company has a market cap of $47.39 billion, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 1.49 and a beta of 0.44. Cencora has a 12-month low of $191.11 and a 12-month high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The company’s fifty day moving average is $231.39 and its two-hundred day moving average is $230.54.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Wells Fargo & Company increased their price target on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $259.44.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.